AlphAIAlphAI — Financial news for AI agents
247wallst.comOCT 292 min read$CAT

Caterpillar Drops 7% as Moderate Sales Outlook Overshadows Beat; Deere Sits Out the Selloff, PACCAR Dips

Caterpillar (CAT) stock fell 7% after reporting Q3 2026 earnings of $7.20 per share, beating estimates, but offering a moderate outlook. Revenue rose 17% to $20.68B. Deere (DE) gained 0.46%, while PACCAR (PCAR) dropped 0.61%. CAT's valuation at 25x forward earnings left little room for modest growth.

Original reporting
247wallst.com
Published Oct 29, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Caterpillar Drops 7% as Moderate Sales Outlook Overshadows Beat; Deere Sits Out the Selloff, PACCAR Dips — source image
Source · 247wallst.com
Decision brief

The 30-second read

$CATBearishHigh
01

Why it matters

The mixed results triggered a 7% drop in Caterpillar shares, highlighting the market's sensitivity to guidance in the AI‑driven data‑center power segment.

02

Market read

The earnings release and guidance revision are the primary drivers of the stock's move, making the article highly relevant for traders.

03

What to watch

Caterpillar's strong backlog and $1.9 B returned to shareholders could support longer‑term upside despite short‑term sell‑off.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Caterpillar beat Q3 earnings expectations but provided only a moderate sales outlook for Q4, while peers Deere and PACCAR posted modest moves.

Company-level read

Ticker impact

$CATBearishHigh confidence
Context

Caterpillar reported Q3 earnings beat but issued only a moderate sales outlook, causing the stock to drop 7% in morning trading.

Expected impact

downward pressure as investors price in the moderate outlook and potential AI spending slowdown.

Evidence & confidence

Guidance below expectations after a beat typically triggers sell‑offs; the stock already fell 7% on the news.

Market effects

Sector

Machinery and power‑equipment sector may see broader pressure as peers are compared to Caterpillar's outlook.

Regional

U.S. industrial stocks could face short‑term weakness.

Global

Limited to investors tracking heavy‑equipment and AI‑linked industrial exposure.

Counterpoint

What could challenge this read

Some investors may view the beat as a sign of resilience and could look for a bounce if the market overreacts to the guidance.

Key entities

  • company
    Caterpillar Inc.

    Heavy‑equipment maker that reported Q3 earnings beat and moderate outlook.

Read at source← All news

StoryCaterpillar beats Q3 profit estimates but keeps outlook unchanged

Also covered by

6 outlets

Related articles

OCT 29
$CATHighAI 8/10

Caterpillar posts ‘highest sales quarter ever,’ fueled by data centers

Caterpillar reported Q3 2026 net sales of $20.7B, up 17% YoY, and profit of $3.3B, up 43% YoY. The company cited strong demand for data centers, construction, and mining. Its backlog reached $78B, nearly double YoY. Power and energy division sales grew 18%, led by power generation. Construction industries sales rose 18%, with North America as the top region.

finance.yahoo.com2 min
OCT 29
$CATHighAI 8/10

Caterpillar’s Earnings Plunge Hits These 3 Popular ETFs Hardest

Caterpillar (CAT) shares fell 7.27% after its Q3 earnings report, with revenue missing expectations. The company's performance impacted three popular ETFs: Industrial Select Sector SPDR Fund (XLI), Fidelity MSCI Industrials Index ETF (FIDU), and Vanguard High Dividend Yield ETF (VYM). CAT is down 10.42% over the past week and 19.13% over the past month, despite being up 16.47% year-to-date and 252.29% over five years.

247wallst.com3 min
OCT 29
$LLYMed

Eli Lilly climbs on strong Q3 earnings results

Eli Lilly reported strong Q3 earnings, raising its full-year forecast. Key drugs Mounjaro and Zepbound generated $10.7B and $5.35B in sales, respectively, contributing to total revenue of $24.4B. The company also announced positive study results for Retatrutide, aiming for approval in 2027. Shares are up 20% year-to-date, contrasting with Novo Nordisk's 25% decline.

finance.yahoo.com7 min
OCT 29
$GOOGLMed

US Stocks Fall, Alphabet Tumbles

US stocks declined on Thursday, with the S&P 500 down 0.5%, Nasdaq down 1.4%, and Dow down 310 points. Alphabet fell 12% after missing earnings and revenue expectations. Amazon and Intel also dropped ahead of their earnings reports. Caterpillar fell nearly 12% due to moderate sales growth forecasts. Microsoft rose 0.8% on strong cloud sales. Eli Lilly and Merck gained 7.3% and 3.3%, respectively, after raising their revenue outlooks.

tradingview.com3 min